2936eP Immune checkpoint inhibitor rechallenge in combination with siltuximab prophylaxis for patients who had prior immune-related adverse event: Preliminary safety results from the phase 2 CIRES trial. - Yang, Y.A.; Mortazavi, A.; Presley, C.; Konda, B.; Backes, F.; Mittra, A.; Hasanov, M.; Zimmerman, D.; Leibner, D.; Wu, R.; rubinstein, M.; Wei, L.; et al. (Annals of Oncology, 2025)